A bearish view on AMED stock suggests caution due to its pending acquisition by UnitedHealth Group, which introduces uncertainty. The stock is currently trading at $91.93, below the analyst price target of $101, reflecting limited upside potential. Additionally, concerns over adjusted EBITDA estimates and a negative long-term EPS growth rate (-3%) further justify a hold or sell stance.